Share Email Print

Proceedings Paper

In vitro and in vivo antitumor efficacy of berberine-nanostructured lipid carriers against H22 tumor
Author(s): Zhi-ping Wang; Junbiao Wu; Tong-sheng Chen; Qun Zhou; Yi-fei Wang
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Hepatocarcinoma, a malignant cancer, threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistance of the advanced hepatocarcinoma to chemotherapy. Berberine (Ber), an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-hepatocarcinoma effects. However its low oral bioavailability restricts its wide application. In this report, Ber loaded nanostructured lipid carriers (Ber-NLC) was prepared by hot melting and then high pressure homogenization technique. Both in vitro and in vivo anti-hepatocarcinoma effects of Ber-NLC relative to efficacy of bulk Ber were evaluated. The particle size and zeta potential of Ber-NLC were 189.3 nm and −19.3 mV, respectively. MTT assay showed that Ber-NLC effectively inhibited the proliferation of H22 cells, and the corresponding IC50 values were 6.3 μg/ml (22.1 μg/ml of bulk Ber). In vivo studies also showed higher antitumor efficacy, and inhibition rates was 68.3 % (41.4 % of bulk Ber) at 100 mg/kg intragastric administration in the H22 solid tumor bearing mice. These results suggest that the delivery of Ber-NLC is a promising approach for treating tumors.

Paper Details

Date Published: 9 March 2015
PDF: 8 pages
Proc. SPIE 9324, Biophotonics and Immune Responses X, 93240Y (9 March 2015); doi: 10.1117/12.2079107
Show Author Affiliations
Zhi-ping Wang, Guangdong Pharmaceutical Univ. (China)
Junbiao Wu, Guangzhou Univ. of Chinese Medicine (China)
Tong-sheng Chen, South China Normal Univ. (China)
Qun Zhou, Huazhong Univ. of Science and Technology (China)
Yi-fei Wang, Jinan Univ. (China)

Published in SPIE Proceedings Vol. 9324:
Biophotonics and Immune Responses X
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?